Protein Sciences takes on Big Pharma in vaccines race
Big Pharma has a big stake in creating new flu vaccines, but tiny Protein Sciences in Connecticut believes it can get a new vaccine approved in '08. The big trend in vaccines today is to move away from egg-based production and into cell-based production, and Protein Sciences' approach is to inject flu genes into caterpillar cells. The protein that is expressed is used in the vaccine. The company may be small, but it has some big names at the top. CEO Daniel Adams is a co-founder of Biogen and David Fedson comes from Sanofi-Aventis.
- read the report from the Wall Street Journal (sub. req.)
Related Article:
Vaccine "renaissance" attracts huge new venture investments. Report
Be the first to comment
More stories about Sanofi Aventis cells flu vaccines genes Protein Sciences Egg-based Daniel Adams pharmaceuticals
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
